FY2025 · ended Dec 31, 2025 · Revenue $61.16B, +8.6% YoY · Filed Feb 20, 2026
AbbVie Inc. (ABBV) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $61.2 billion and net income of $4.2 billion. Free cash flow was $17.8 billion. As of Sep 30, 2026 it held $11.2 billion in cash and investments and $0 in total debt.
Revenue (TTM)
$66.01B
+10.7% vs year-ago TTM
Net income (TTM)
$10.34B
+333.1% vs year-ago TTM
Operating cash flow (TTM)
$20.09B
-3.7% vs year-ago TTM
Free cash flow (TTM)
$18.87B
-4.1% vs year-ago TTM
EPS (TTM)
$5.81
+338.8% vs year-ago TTM
Dividend per share
$6.65
+5.7% vs prior year
Shares outstanding
1.77B
+0.2% vs prior year
Net cash
$11.16B
as of Sep 30, 2026
Operating margin
32.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABBV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- North Chicago, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1551152
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $61.2B | $56.3B | $54.3B | $58.1B | $56.2B |
| Operating income | $15.1B | $9.1B | $12.8B | $18.1B | $17.9B |
| Net income | $4.2B | $4.3B | $4.9B | $11.8B | $11.5B |
| Diluted EPS | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
| Operating cash flow | $19.0B | $18.8B | $22.8B | $24.9B | $22.8B |
| Free cash flow | $17.8B | $17.8B | $22.1B | $24.2B | $22.0B |
| Total assets | $134.0B | $135.2B | $134.7B | $138.8B | $146.5B |
| Stockholders' equity | -$3.3B | $3.3B | $10.4B | $17.3B | $15.4B |
| Cash and investments | $5.5B | $5.8B | $13.1B | $9.5B | $10.1B |
| Total debt | $67.9B | $67.8B | $60.2B | $64.1B | $76.9B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Nov 2, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 30, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 3, 2026 | Sep 3, 2026 |
All 1006 AbbVie Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.